Navigation Links
Simcere Pharmaceutical Group to Announce Second Quarter 2008 Earnings on Tuesday, August 5, 2008
Date:7/15/2008

HREF="http://www.simcere.com" target="_new">http://www.simcere.com for seven days following the earnings announcement.

About Simcere Pharmaceutical Group

Simcere Pharmaceutical Group (NYSE: SCR) is a leading manufacturer and supplier of branded generic and innovative anti-cancer pharmaceuticals in the rapidly growing China market. In recent years, Simcere Pharmaceutical Group has focused its strategy on the development of first-to-market generic and innovative pharmaceuticals, and has introduced a first-to-market generic anti-stroke medication under the brand name Bicun and an innovative anti-cancer medication under the brand name Endu. It currently manufactures and sells 39 principal pharmaceutical products including antibiotics, anti-cancer medication and anti-stroke medication and is the exclusive distributor of three additional pharmaceuticals that are marketed under its brand names. Simcere concentrates its research and development efforts on the treatment of diseases with high incidence and/or mortality rates and for which there is a clear demand for more effective pharmacotherapy such as cancer, strokes, osteoporosis and infectious diseases. For more information about Simcere Pharmaceutical Group, please visit http://www.simcere.com.

For investor and media inquiries, please contact:

Email: ir@simcere.com

In Nanjing:

Frank Zhigang Zhao

Chief Financial Officer

Simcere Pharmaceutical Group

Tel: +86-25-8556 6666 ext. 8818

In Beijing:

Kejia Wu

Brunswick Group

Tel: +8610 6566 2256

In Hong Kong:

Joseph Lo Chi-Lun

Brunswick Group

Tel: +852
'/>"/>

SOURCE Simcere Pharmaceutical Group
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Simcere Pharmaceutical Group to Announce Third Quarter 2007 Earnings on Monday, November 5, 2007
2. Simcere Pharmaceutical Group Announces the Appointment of New Vice President of Marketing and Two Senior Promotions
3. Simcere Pharmaceutical Group Reports Proposed Private Sale of Ordinary Shares by Existing Shareholder
4. Simcere Pharmaceutical Group to Participate in Credit Suisse 3rd Annual Healthcare Trip
5. Simcere Pharmaceutical Group to Participate in Upcoming Investor Conferences in New York
6. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
7. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
8. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
9. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
10. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
11. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2014)... , Aug. 26, 2014  ViveBio, LLC ... sample collection, stabilization and transportation, announced today that ... Procurement Services, LLC (LPS) of Knoxville, ... products in the United States ... class of ambient temperature dried biological specimen transport ...
(Date:8/26/2014)... (PRWEB) August 26, 2014 Vycom announced ... CA, which specializes in chemical process equipment, has selected ... State University’s Facility for Rare Isotope Beams (FRIB). ... precision cleaning line made with Vycom’s Flametec PVC-C and ... are the essential parts of FRIB’s linear accelerator (known ...
(Date:8/26/2014)... 2014  Guardant Health, a healthcare company focused ... products, has been recognized today by the World ... . As an innovator in non-invasive, tumor profiling, ... a wide variety of industries and regions to ... ® , Guardant Health,s first commercially available product, ...
(Date:8/26/2014)... 26, 2014 After searching for ... research facilities , the University of Kansas Medical ... have chosen iLab Solutions' web-based core facility management ... , "We are very pleased that the ... Center signed on with us,” stated Heather Lorenz, ...
Breaking Biology Technology:ViveBio and Laboratory Procurement Services Sign Agreement for Distribution of the ViveST Line of Products 2Modutek Selects Vycom’s Flametec Materials for Michigan State University’s Superconductor Equipment 2Modutek Selects Vycom’s Flametec Materials for Michigan State University’s Superconductor Equipment 3Guardant Health Named a 2015 Technology Pioneer by World Economic Forum 2The University of Kansas Medical Center and The University of Kansas Cancer Center Select iLab Solutions Web-based Software to Streamline Operations 2The University of Kansas Medical Center and The University of Kansas Cancer Center Select iLab Solutions Web-based Software to Streamline Operations 3
... Company also Initiates the Phase 2b ASTUTE Clinical Trial ... Therapeutics, Inc., a privately held biopharmaceutical company, announced that ... the treatment of patients with low-grade hepatic encephalopathy was ... the European Association for the Study of Liver Disease ...
... palliation as an acceptable primary endpoint, ... WA, April 28 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: ... has reached an agreement with the U.S. Food and ... Phase 3 registration trial of OGX-011, its lead product ...
... compliance and persistence with chronic medications. Prescription refills increase up ... free service offers coaching, reminders and pharmacist support to alleviate ... - prescribed medication. , ... ...
Cached Biology Technology:Ocera Therapeutics Presents Data on AST-120 in Patients With Hepatic Encephalopathy at the European Association for the Study of Liver Disease Annual Meeting 2Ocera Therapeutics Presents Data on AST-120 in Patients With Hepatic Encephalopathy at the European Association for the Study of Liver Disease Annual Meeting 3OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer 2OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer 3OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer 4OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer 5OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer 6New Pleio Medication Adherence Service Increases Prescription Refills Up To 53% 2
(Date:8/26/2014)... in St. Louis have developed algorithms to identify weak ... or breaking. The technology, which needs to be refined ... help pinpoint minor strains and tiny injuries in the ... research is available online Aug. 27 in the ... research at the nexus of the physical and life ...
(Date:8/26/2014)... a pen a New Zealand endemic tree has for the ... group of ,weedy, Australian shrubs and small trees. A New ... surprises and discover astonishing cryptic diversity behind what was long ... the open access journal PhytoKeys . , ... was one of the many discoveries made in the north-western ...
(Date:8/26/2014)... -- Unregulated trash burning around the globe is pumping ... official records. A new study led by the National ... percent of the world,s garbage is burned in such ... human health and climate change. , The new study ... of pollutants such as particulates, carbon monoxide, and mercury ...
Breaking Biology News(10 mins):New technology may identify tiny strains in body tissues before injuries occur 2New technology may identify tiny strains in body tissues before injuries occur 3And then there were 10 -- unexpected diversity in New Zealand kanuka genus Kunzea 2And then there were 10 -- unexpected diversity in New Zealand kanuka genus Kunzea 3Trash burning worldwide significantly worsens air pollution 2Trash burning worldwide significantly worsens air pollution 3
... Fifty-nine leading life scientists from Europe and around the ... Organization (EMBO) for their proven excellence in research. Fifty-one ... Europe and neighbouring countries, while eight equally respected scientists ... as Associate Members, bringing the current membership total to ...
... herbicide that is effective at killing broadleaf weeds in ... Illinois and other Midwestern states, may finally have a ... developed a new grape called Improved Chancellor which is ... 1946, 2,4-Dichlorophenoxyacetic or 2, 4-D was introduced. It was ...
... is available in Spanish . An ... the Institute for Research in Biomedicine (IRB Barcelona) and ... (ICIQ, Tarragona), have discovered a substance with the capacity ... certain mutations that promote the appearance of cancer. Giralt, ...
Cached Biology News:EMBO honors 59 leading life scientists 2Herbicide-resistant grape could revitalize Midwest wine industry 2Herbicide-resistant grape could revitalize Midwest wine industry 3Design of a compound that stabilizes the main natural suppressor of tumors 2
tracking dye in electrophoresis; free acid, C 19 H 10 BrO 5 S; MW: 669.96...
... Last innovation from Magnetofection technology, SilenceMag ... system available. Simple, rapid and easy ... and non toxic. Specifically designed for ... silencing at very low doses of ...
... Last innovation from Magnetofection technology, ... delivery system available. Simple, rapid and ... compatible and non toxic. Specifically designed ... gene silencing at very low doses ...
... Test Plate consists of an anodized aluminum ... Organic Fluorescent Compounds embedded in polymerized matrix. ... BioTeks FLx800 and Synergy Multi-Detection Readers. This ... compliance while reducing the need for tedious ...
Biology Products: